SMC accepts rivaroxaban (Xarelto®) for treatment of PE and prevention of recurrent DVT or PE

Source: Scottish Medicines Consortium (SMC) Area: Evidence > Drug Specific Reviews The Scottish Medicines Consortium has accepted rivaroxaban (Xarelto®) for the treatment of pulmonary embolism (PE), and prevention of recurrent deep vein thrombosis (DVT) and PE in adults in NHS Scotland.   According to the SMC advice, rivaroxaban was non-inferior to a regimen including a low molecular weight heparin and a vitamin K antagonist for the treatment of PE and the prevention of recurrence of DVT or PE.  The duration of treatment was 3, 6 or 12 months at the discretion of the treating physician. Experience with rivaroxaban in this indication for more than 12 months is limited therefore the cost-effectiveness of indefinite treatment has not been demonstrated.
Source: NeLM - Cardiovascular Medicine - Category: Cardiology Source Type: news